Goodwin advised Jeito Capital on the fundraising of its second fund, Jeito II, exceeding its target at $1.2 billion (above €1 billion).
This fundraising is the largest ever achieved by a fully independent European fund dedicated to Biopharma.
The fund was highly attractive to top-tier international investors, reflecting their strong conviction in Jeito’s ability to capitalize on the compelling opportunity in Biopharma. It has been backed by a diversified base of investors across Europe, North America, and Asia, including sovereign and public funds, pharmaceutical and corporate investors, insurance companies, pension funds, family offices, foundations, endowments, and banks.
Jeito II will continue the strategy established with Jeito I: selectively identifying and backing 15 to 20 of the most promising clinical-stage Biopharma companies, primarily in Europe, developing breakthrough therapies for severe diseases with high unmet medical needs and accelerating the development path and future market access.
This fundraising allows Jeito to increase the average size of future investments in portfolio companies up to €150 million, thus driving value creation by enabling the companies to accelerate and progress through to advanced clinical development and unleash their full commercial potential.
Jeito II has already actively deployed capital in therapeutic areas with strong demand: i.e. obesity, reproductive medicine, oncology, autoimmune and inflammatory diseases, neurology, and cardio-metabolic diseases.
The Goodwin team included:
- in France, Arnaud David, Sarah Barrau-Ceville, Khalilou Gneny, and Olivia Doble on fundraising matters and Marie-Laure Bruneel on tax matters;
- in the US, Brynn Peltz and William Stern on regulatory matters and Romina Weiss on tax matters.